APA: Duloxetine Has Little Effect on Body Weight
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




APA: Duloxetine Has Little Effect on Body Weight

By Bruce Sylvester

PHILADELPHIA, PA -- May 24, 2002 -- The investigative antidepressant duloxetine has no clinically meaningful effects on body weight in most patients, researchers reported at the annual meeting of the American Psychiatric Association (APA).

"The most important implication of this research, which combines several studies, is that, overall, the effect of duloxetine is weight neutral," said Robert Brannon, MD, clinical research physician, Eli Lilly Laboratories, Indianapolis, Indiana.

The investigators pooled data from seven double-blind, placebo-controlled trials in which 1,032 patients were given duloxetine 40 mg/day to 120 mg/day and 732 received placebo. Patients were treated for up to 12 weeks.

The investigators also analyzed data from a 12-month, open-label, single-arm study of 1,282 patients.

Patients receiving duloxetine in the placebo-controlled trials lost approximately 0.5 kg, compared with a gain of 0.2 kg for placebo subjects (p<0.001).

The incidence of decreased appetite was significantly greater for duloxetine patients (6.5 percent) compared to placebo patients (2.1 percent), as was the incidence of decreased body weight (1.7 percent vs. 0.6 percent).

The incidence of increased appetite was lower for duloxetine patients (1.2 percent vs. 1.5 percent), and the incidence of increased body weight was significantly lower for duloxetine patients (0.3 percent vs. 1.2 percent).

In the open-label study, mean change to end point for duloxetine patients was 1.12 kg (p<0.001).

The research was supported by Eli Lilly and Company.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities